HomeCompareCMRX vs RYLD

CMRX vs RYLD: Dividend Comparison 2026

CMRX yields 23.42% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMRX wins by $44.6K in total portfolio value
10 years
CMRX
CMRX
● Live price
23.42%
Share price
$8.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$89.9K
Annual income
$9,559.82
Full CMRX calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — CMRX vs RYLD

📍 CMRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMRXRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMRX + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMRX pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMRX
Annual income on $10K today (after 15% tax)
$1,990.63/yr
After 10yr DRIP, annual income (after tax)
$8,125.85/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, CMRX beats the other by $5,845.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMRX + RYLD for your $10,000?

CMRX: 50%RYLD: 50%
100% RYLD50/50100% CMRX
Portfolio after 10yr
$67.6K
Annual income
$6,121.40/yr
Blended yield
9.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CMRX right now

CMRX
Analyst Ratings
14
Buy
9
Hold
2
Sell
Consensus: Buy
Price Target
$8.55
+0.1% upside vs current
Range: $8.55 — $8.55
Altman Z
10.0
Piotroski
4/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMRX buys
0
RYLD buys
0
No recent congressional trades found for CMRX or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMRXRYLD
Forward yield23.42%12.39%
Annual dividend / share$2.00$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$89.9K$45.3K
Annual income after 10y$9,559.82$2,682.98
Total dividends collected$55.2K$19.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CMRX vs RYLD ($10,000, DRIP)

YearCMRX PortfolioCMRX Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$13,042$2,341.92$11,939$1,239.34+$1.1KCMRX
2$16,809$2,854.50$14,158$1,382.89+$2.7KCMRX
3$21,424$3,438.39$16,682$1,532.59+$4.7KCMRX
4$27,020$4,095.71$19,537$1,687.64+$7.5KCMRX
5$33,739$4,827.47$22,752$1,847.20+$11.0KCMRX
6$41,734$5,633.54$26,355$2,010.43+$15.4KCMRX
7$51,168$6,512.66$30,376$2,176.45+$20.8KCMRX
8$62,212$7,462.49$34,847$2,344.43+$27.4KCMRX
9$75,047$8,479.64$39,800$2,513.54+$35.2KCMRX
10$89,860$9,559.82$45,269$2,682.98+$44.6KCMRX

CMRX vs RYLD: Complete Analysis 2026

CMRXStock

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Full CMRX Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this CMRX vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMRX vs SCHDCMRX vs JEPICMRX vs OCMRX vs KOCMRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.